Sanofi (EPA:SAN)
France · Delayed Price · Currency is EUR | Market Cap | 98.93B -21.8% |
| Revenue (ttm) | 46.72B +5.5% |
| Net Income | 7.81B +40.5% |
| EPS | 6.40 +44.2% |
| Shares Out | 1.21B |
| PE Ratio | 20.22 |
| Forward PE | 9.80 |
| Dividend | 4.12 (5.03%) |
| Ex-Dividend Date | May 12, 2025 |
| Volume | 440,892 |
| Average Volume | 2,010,904 |
| Open | 81.94 |
| Previous Close | 81.84 |
| Day's Range | 80.64 - 82.06 |
| 52-Week Range | 76.15 - 110.88 |
| Beta | 0.37 |
| RSI | 49.95 |
| Earnings Date | Jan 29, 2026 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepati... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial StatementsNews
Sanofi (SNY) Announces â¬1B Share Buyback Program
Sanofi (SNY) Announces â¬1B Share Buyback Program
Sanofi Signs Mandate For EUR 1 Bln Share Buyback
(RTTNews) - Sanofi (SNY, SAN.PA), a French pharmaceutical and healthcare company, on Monday said it has signed a mandate to execute a 1 billion euros share buyback program in 2026.
Sanofi signs share buyback for up to €1B
Sanofi's (SAN) Venglustat Achieves Key Milestone in Gaucher Disease Trial
Sanofi's (SAN) Venglustat Achieves Key Milestone in Gaucher Disease Trial
Sanofi's venglustat demonstrates mixed results in late-stage rare disease trials
Sanofi Found In Breach Of UK Pharmaceutical Marketing Code Over Beyfortus Claims
Sanofi SA (NASDAQ: SNY) has been found to have violated the U.K.'s pharmaceutical marketing code after a senior executive made misleading claims in an October 2024 interview, prompting a complaint fr...
UK industry body says Sanofi in breach over RSV therapy claims against Pfizer
Sanofi has breached the UK pharma code of practice with unsubstantiated claims that its Beyfortus was more effective than Pfizer's RSV vaccine, the industry's self-regulatory body said on Monday, resp...
Sanofi's Venglustat Hits Main Goal In Gaucher Study, Falls Short In Fabry Disease
(RTTNews) - Sanofi (SNY) announced that its investigational drug Venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease while it did not meet the primary endpoint in a phase...
Sanofi: Venglustat Meets All Primary Endpoints In Phase 3 Study Of Type 3 Gaucher Disease
(RTTNews) - Sanofi (SNY, SAN.PA) reported that the LEAP2MONO phase 3 study demonstrated that venglustat met the primary and three out of four key secondary endpoints in adults and pediatric patients w...
Sanofi's genetic disorder drug shows mixed results in late-stage trials
French drugmaker Sanofi said on Monday that its experimental genetic disorder treatment showed promise in a late-stage study of patients with a type of Gaucher disease, but failed to meet the main goa...
Sanofi (SNY) Gains Positive EU Nod for Rezurock Approval
Sanofi (SNY) Gains Positive EU Nod for Rezurock Approval
Dynavax President and COO Sells 114,000 Shares on Sanofi Acquisition News
This vaccine-focused biotech reported a significant insider sale as it advances its hepatitis B franchise and global partnerships.
Sanofi graft-versus-host disease asset Rezurock gains EU approval recommendation
Sanofi (SNY) Gains EU Panel Support for Rezurock Approval
Sanofi (SNY) Gains EU Panel Support for Rezurock Approval
Regeneron posts Q4 beat as Sanofi collaboration offsets Eylea headwinds
Press Release: Sanofi's Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease
Sanofi's Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease Recommendation supported by safety and efficacy results from several clinical studies and real-world ev...
Sanofi SA (SNY) Q4 2025 Earnings Call Highlights: Strong Sales Growth and Strategic ...
Sanofi SA (SNY) Q4 2025 Earnings Call Highlights: Strong Sales Growth and Strategic Acquisitions Propel Performance
Sanofi (SAN:CA) Q4 2025 Earnings Call Transcript
Sanofi (SAN:CA) Q4 2025 Earnings Call Transcript
Q4 2025 Sanofi SA Earnings Call Transcript
Q4 2025 Sanofi SA Earnings Call Transcript
Sanofi Creeps Higher On 'Essentially In Line' Guidance For 2026
Sanofi stock rose slightly early Thursday on better-than-expected earnings and in line guidance for the current year.
Sanofi 2025 Q4 - Results - Earnings Call Presentation
Sanofi (SNY) Projects Profitable Growth and Announces Share Buyback for 2026
Sanofi (SNY) Projects Profitable Growth and Announces Share Buyback for 2026
Sanofi (SNY) Reports Strong EPS Growth and Sales Performance
Sanofi (SNY) Reports Strong EPS Growth and Sales Performance
Sanofi Warns Dupixent Is Too Big To Replace As Patent Clock Ticks
Sanofi SA (NASDAQ: SNY) reported fourth-quarter sales of $13.159 billion (11.30 billion euros) on Thursday, missing the consensus of $13.41 billion . Sales increased 7% year over year, up 13.3% in co...
Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite
Drugmakers Roche and Sanofi posted full-year earnings that matched expectations and did little to move either stock. As pharma companies face a "patent cliff" where existing drugs lose exclusivity, th...